Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.

ABSTRACT:

Aim

To compare the cardiovascular risks between users and non-users of sodium-glucose co-transporter-2 (SGLT2) inhibitors based on electronic medical record data from a large integrated healthcare system in South Louisiana.

Materials and methods

Demographic, anthropometric, laboratory and medication prescription information for patients with type 2 diabetes who were new users of SGLT2 inhibitors, either as initial treatments or as add-on treatments, were obtained from electronic health records. Mediation analysis was performed to evaluate the association of use of SGLT2 inhibitors and changes of metabolic risk factors with the risk of incident ischaemic heart disease.

Results

A total of 5338 new users of SGLT2 inhibitors were matched with 13 821 non-users. During a me

SUBMITTER: Shen Y 

PROVIDER: S-EPMC7547648 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature